Skip to main content
. 2025 Apr 29;16:1587658. doi: 10.3389/fimmu.2025.1587658

Table 1.

Baseline characteristics of the whole cohort in SYSUCC, JMCH, and HNCH.

Characteristics Level SYSUCC JMCH HNCH
N = 71 N = 31 N = 29
Age, no. (%) <65 47 (66.2) 20 (64.5) 18 (62.1)
≥65 24 (33.8) 11 (35.5) 11 (37.9)
Sex, no. (%) Male 58 (81.7) 28 (90.3) 28 (96.6)
Female 13 (18.3) 3 (9.7) 1 (3.4)
Smoking history, no. (%) Never 18 (25.4) 5 (16.1) 6 (20.7)
F/C 53 (74.6) 26 (83.9) 23 (79.3)
ICI types, no. (%) PD-1 68 (95.8) 28 (90.3) 29 (100.0)
PD-L1 3 (4.2) 3 (9.7) 0 (0.0)
Neoadjuvant treatment cycle, no. (%) ≤3 61 (85.9) 23 (74.2) 25 (86.2)
>3 10 (14.1) 8 (25.8) 4 (13.8)
Clinical stage, no. (%) IB 4.97 (1.92) 4.92 (2.02) 4.21 (1.54)
IIA 3 (4.2) 2 (6.5) 1 (3.4)
IIB 0 (0.0) 1 (3.2) 2 (6.9)
IIIA 37 (52.1) 15 (48.4) 19 (65.5)
Clinical N stage, no. (%) N0 31 (43.7) 13 (41.9) 7 (24.1)
N1 41 (57.7) 19 (61.3) 15 (51.7)
Radiology exam types, no. (%) CT 30 (42.3) 12 (38.7) 14 (48.3)
PET/CT 57 (80.3) 21 (67.7) 21 (72.4)
Tumor histology, no. (%) LUSC 14 (19.7) 10 (32.3) 8 (27.6)
Non-LUSC 23 (32.4) 14 (45.2) 11 (37.9)
Adjuvant treatment status, no. (%) No 48 (67.6) 17 (54.8) 18 (62.1)
Yes 47 (66.2) 20 (64.5) 18 (62.1)

SYSUCC, Sun Yat-sen University Cancer Center; JMCH, Jiangmen Central Hospital; HNCH, Henan Cancer Hospital; ICI, immune checkpoint inhibitor; PD-1, programmed death-1; PD-L1, programmed death-L1; CT, computed tomography; PET, positron emission tomography; LUSC, lung squamous cell carcinoma; F/C, former/current.